Skeletal Muscle Mitochondrial Abnormalities and the Metabolic Syndrome in PAH

Sponsor

Laval University (Other)

Overall Status

Recruiting

CT.gov ID

NCT03979482

Collaborator

(none)

Enrollment

Location

Anticipated Duration (Months)

0.7

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Pulmonary arterial hypertension (PAH) is characterized by the progressive increase in pulmonary vascular resistance ultimately leading to right ventricular (RV) failure. Its prevalence is estimated at 40-60 persons per million and predominantly affects people between 20 and 60 years of age. Newly available therapies have improved the 3-year survival to >80%. This improvement in prognosis brings new challenges for clinicians: PAH has changed from a rapidly fatal disease to a chronic disorder with persistent exercise limitation and poor quality of life.

Many observations suggest that exercise limitation in PAH is not simply due to pulmonary hemodynamic impairment, but that other determinants are involved. Interestingly, even in absence of obesity or diabetes, insulin resistance (IR) and metabolic syndrome (MS) are highly prevalent amongst PAH patients and associated with worse outcomes. Indeed, lipid accumulation in skeletal muscle (a feature of IR) is observed in both human and experimental model of PAH, but its impact on skeletal muscle function and thus exercise intolerance in PAH remains elusive.

Over the past years, several pathophysiological pathways activated by MS have been identified, including the downregulation PPARg/PGC1a and the insulin signalling pathways, especially the insulin-receptor substrate 1 (IRS1)-mediated one. The decrease in these axes is associated with lipid accumulation and impaired mitochondrial function. The investigators previously reported in PAH lungs that the downregulation of these pathways contributes to the establishment of the Warburg effect. This metabolic unbalance contributes to pulmonary artery smooth muscle (PASMC) proliferation, and resistance to apoptosis contributing to PA remodelling. The investigators recently documented that PAH skeletal muscles are less perfused and are also characterized by the presence of a Warburg effect. These features were independent of daily life physical activity. Nonetheless, the origin of these abnormalities and their impact on skeletal muscle function have never been studied. The investigators propose to determine whether or not MS seen in PAH patients impairs mitochondrial functions through an IRS1/PPARg/PGC1-dependent mechanism, which will ultimately decrease skeletal muscle function and perfusion, and thus overall exercise capacity.

Condition or Disease	Intervention/Treatment	Phase
Pulmonary Artery Hypertension

Detailed Description

AIM 1:

To determine whether MS is associated with intramuscular lipid accumulation and impaired skeletal muscle metabolism and perfusion in human PAH.

Rationale: MS and IR are highly prevalent amongst PAH patients even in the absence of obesity and diabetes. There are several lines of evidence in the literature that IR develops with the accumulation of fatty-acid metabolites within insulin-responsive tissues, especially intramyocellular lipid deposition within skeletal muscles. Although the mechanism accounting for lipid accumulation remains elusive, a reduction in lipid oxidation as a result of reduction in mitochondrial density has been proposed. The objectives of Aim 1 are 1) to confirm that PAH patients have increased intramuscular lipid accumulation; 2) to determine whether intramuscular lipid accumulation is associated with impaired skeletal muscle metabolism; 3) to demonstrate that these abnormalities correlate with MS and IR and skeletal muscle function amongst PAH patients.

Experimental approaches: The proposed experiments will be performed on PAH patients (n=10-20) vs. 10 healthy but sedentary subjects matched for age, gender, height and weight (definition based on current recommendations), excluding patients with clinically relevant conditions (e.g. diabetes). These individuals are continuously identified through our systematic plasma biobanking process at the time of right heart catheterization (CER#20735), in which roughly 40% of PAH patients with no obesity/diabetes have MS. In addition to routinely performed analyses: A) blood sample will be drawn for Apolipoprotein A1, Apolipoprotein B, glycated hemoglobin, fasting blood glucose, insulin, adiponectin and leptin. B) MR imaging will be used to assess fat infiltration within the quadriceps muscle, liver and heart (see appendix for details). C) Volitional and non volitional strength and endurance of the dominant quadriceps and VO2peak on cycle ergometer will be assessed, as previously described. D) Percutaneous biopsy specimens of the vastus lateralis muscle of the nondominant leg will be taken. Part of the specimen (≈100mg) will be used for immunohistochemistry fiber typing (ethanol modified technique), capillarisation (quantitative IF using CD31-antibody) and intramyocellular lipid accumulation (Oil red O staining, which stains only the most hydrophobic and neutral lipids, as the investigators previously described. The extracellular flux analyzer Seahorse XF24 will be used on the remaining tissues for real time measurements of oxygen consumption and extracellular acidification rates (glycolysis). To ensure that physical inactivity is not responsible for skeletal muscle lipid accumulation, subjects' daily life physical activities will be objectively quantified during one week using a physical activity monitor (SenseWear® armband).

Interpretation: This multimodality approach will provide comprehensive information to confirm: 1) PAH patients exhibit significant increases in quadriceps muscle lipid accumulation compared to controls; 2) lipid accumulation is increased within the skeletal muscle of PAH patients with MS compared to PAH without MS despite similar levels of physical activity; 3) Lipid accumulation is associated with a reduction in lipid oxidation in vivo; 4) MS/IR and quadriceps muscle function correlate with muscle lipid accumulation/glucose oxidative phosphorylation capacity.

Sample size and analysis: Comparisons between groups will be performed using one-way ANOVA followed by a Tukey-Kramer post-test, after confirmation of normality/equal variances (Levene's test). 10 subjects/group will allow detecting a 1.5±0.5 fold increase in quadriceps muscle lipid accumulation assessed by MRI (primary outcome) with type 1 and 2 errors of 5% and 15%. Based on our preliminary data (Fig.3C), these estimates are conservative.

Alternative approach: Insulin action in the liver has many similarities with insulin action in muscle. Although our proposal focuses on skeletal muscles, ectopic lipid accumulation in the liver is also increasingly recognized as contributing to MS and IR. Since MRI sequences to assess fat infiltration take few minutes only, liver and abdominal adiposity will be assessed during the same exam MR study, as previously described.

AIM 2:

To assess whether IR and MS is related to defects in insulin signalling within PAH skeletal muscles.

Rationale: Numerous studies confirmed a reduction in expression of the peroxisome proliferator-activated receptor (PPAR) γ coactivator 1α in the muscles of patients with type 2 diabetes mellitus, reducing the mitochondrial fatty acid oxidation that promotes the accumulation of diacylglycerol within the muscle. In skeletal muscles, insulin binds to its receptor, activating the receptor tyrosine kinase activity, with subsequent phosphorylation and activation of insulin-receptor substrate 1 (IRS1), ultimately promoting the docking and fusion of glucose transporter (GLUT4)-containing vesicles to the plasma membrane. Accumulation of intracellular diacylglycerol has been shown to specifically activate protein kinases C (PKC) θ, resulting in reduction in tyrosine phosphorylation of IRS1. Consistently, activation of muscle PKCθ and increased serine (inactivation) phosphorylation of IRS1 has been noted in the muscles of individuals with type 2 diabetes mellitus and IR. More recently, the activation of the nuclear respiratory factor-2 (NRF2)-Keap1 pathway (improving mitochondrial oxygen consumption, ATP production and beta-oxidation of fatty acids) has been shown to reduce glucose uptake and IR.

Experimental approaches: The same experimental groups and experimental design as described in aim 1 will be used. A) In order to examine the mechanisms responsible for the reduction of mitochondrial activity in PAH skeletal muscles, the expression of several key transcriptional factors and coregulators that are known to regulate mitochondrial biogenesis will be examined, including PPARγ coactivator 1α (PGC-1α), NRF-2, and mitochondrial transcription factor A (WB and immunoprecipitation assay). Mitochondrial oxidative (citrate synthase, hexokinase) and glycolytic (lactate dehydrogenase, phosphofructokinase) enzymes activity (spectrophotometric techniques) will also be assessed. B) In order to assess the potential role of IRS-1 serine phosphorylation in the pathogenesis of IR, the investigators will also examine IRS-1 serine phosphorylation on several serine residues (Ser307, Ser312, Ser616, Ser636) that have been implicated to interfere with insulin signaling in vitro (WB). PKCθ expression and activity will be assessed using isoform-specific PKC antibodies (WB) and a PKC enzyme assay kit.

Interpretation: The investigators expect to demonstrate that: 1) PAH patients exhibit reduced expression/activation of PPARγ1α, and NRF-2, increased phosphorylation of IRS-1 on critical serine sites and PKCθ activation, leading to a metabolic shift toward glycolysis; 2) these abnormalities dominate amongst PAH-MS patients compared to PAH without MS.

Alternative approach: PKCθ activation has been predominantly associated with MS. However, the same experiments could be done for other members of the PKC gene family. In the event that "classical MS pathways" described above do not account for IR/MS in PAH, the role of skeletal muscle Uncoupling Protein-2 and Sirtuin-3, which have recently been implicated in both IR/MS and PAH, will be explored.

Study Design

Study Type:

Observational

Anticipated Enrollment :

30 participants

Observational Model:

Case-Control

Time Perspective:

Prospective

Official Title:

Skeletal Muscle Mitochondrial Abnormalities and the Metabolic Syndrome in Pulmonary Arterial Hypertension

Actual Study Start Date :

Jun 1, 2019

Anticipated Primary Completion Date :

Dec 1, 2022

Anticipated Study Completion Date :

Dec 1, 2022

Arms and Interventions

Arm	Intervention/Treatment
PAH patients Male and female subjects, aged between 20 and 60 years old. Absence of obesity/diabètes. PAH patients presenting with metabolic syndrome (MS).
Sedentary healthy patients Male and female subjects, aged between 20 and 60 years old. Absence of obesity/diabètes. Healthy but sedentary subjects.

Outcome Measures

Primary Outcome Measures

Concentration of Intramuscular lipid [Through study completion, an average of 1 year]
MR imaging will be used to assess fat infiltration within the quadriceps muscle, liver and heart.
Level of physical activity [During 1 week]
Subjects' daily life physical activities quantified using a physical activity monitor (SenseWear® armband).
Level of mitochondrial activity in PAH skeletal muscles [Through study completion, an average of 1 year]
The expression of several key transcriptional factors and coregulators that are known to regulate mitochondrial biogenesis will be examined, including PPARγ coactivator 1α (PGC-1α), NRF-2, and mitochondrial transcription factor A (WB and immunoprecipitation assay). Mitochondrial oxidative (citrate synthase, hexokinase) and glycolytic (lactate dehydrogenase, phosphofructokinase) enzymes activity (spectrophotometric techniques) will also be assessed.
Change in serine residues (Ser307, Ser312, Ser616, Ser636) due to IRS-1 serine phosphorylation [Through study completion, an average of 1 year]
Differences in phosphorylation of IRS-1 on critical serine residues (Ser307, Ser312, Ser616, Ser636) that have been implicated to interfere with insulin signaling in vitro will be assessed on skeletal muscle biopsies by Western Blot.
Level of PKCθ activation/activity [Through study completion, an average of 1 year]
Will be assessed on skeletal muscle biopsies using isoform-specific PKC antibodies (WB) and a PKC enzyme assay kit.

Eligibility Criteria

Criteria

Ages Eligible for Study:

20 Years to 60 Years

Sexes Eligible for Study:

All

Inclusion Criteria:

PAH patients: Male and female subjects, patients presenting with metabolic syndrome (MS).
Sedentary healthy patients: Male and female subjects. Healthy but sedentary subjects.